skip to content
Primary navigation


DrugTagrisso™ (osimertinib) [AstraZeneca Pharmaceuticals LP]

May 2016

Therapeutic Area - Oncology

Approval criteria

  • Patient must be 18 years of age or older AND
  • Must have a diagnosis of metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test (copy of test results must be submitted at time of request) AND
  • Have had disease progression on or after EGFR TKI therapy

Quantity limit

  • Maximum of 34 tablets per 34 days


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top